[Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment

<div>DEGs in B lymphocytes of CLL patients. (a) The top 20 genes with the largest expression in each group. (b) The DEGs of patient 1, compared between observation stage and post-CIT. (c) The DEGs of patient 1, compared between pre-CIT and post-CIT. (d, e) The DEGs of patient 2 and 3, compared between pre-CIT and post-CIT.</div>

Computational and Mathematical Methods in Medicine

fig2

Figure 2

Figure 2: [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 

Figure 2 | [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 